Integrated Biopharma Valuation

Integrated Biopharma Investor Information

About 69.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.56. Some equities with similar Price to Book (P/B) outperform the market in the long run. Integrated Biopharma had not issued any dividends in recent years. Based on the key measurements obtained from Integrated Biopharma's financial statements, Integrated Biopharma is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.

Integrated Biopharma Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Integrated Biopharma has an asset utilization ratio of 222.76 percent. This connotes that the OTC Stock is making $2.23 for each dollar of assets. An increasing asset utilization means that Integrated Biopharma is more efficient with each dollar of assets it utilizes for everyday operations.

Integrated Biopharma Ownership Allocation

Integrated Biopharma has a total of 29.95 Million outstanding shares. Integrated Biopharma retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 68.58 (percent) of Integrated Biopharma outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Integrated Biopharma Profitability Analysis

The company reported the previous year's revenue of 56.25 M. Net Income was 3.84 M with profit before overhead, payroll, taxes, and interest of 6.55 M.

Investing in growth stocks can be very risky. If the company such as Integrated Biopharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

If you are still planning to invest in Integrated Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Integrated Biopharma's history and understand the potential risks before investing.